Overview
Summary
With the application of the MoGRAA® discovery engine and technology, we are developing first-in-class new drug candidates for clinical development, focusing on respiratory diseases, chronic inflammation and severe viral infections. We are exploring partnerships for clinical development and commercialization in the global market.
Internal pipelines are available for partnering opportunity
| Project | 1st Indication | 2nd Indication | Target GPCR | Patent | Development stage |
|---|---|---|---|---|---|
| P-001 | Autoimmune disease | Cancer immunity | EP4 | Issued | Manufacturing Preparation |
| P-007 | Lung fibrosis | Gastrointestinal solid cancer | CCR7 | Issued | Manufacturing Preparation |
| P-013 | Fibrosis | Pain | Lipid GPCR | Lead mAb exploring | |
| P-014 | Severe Virus infection disease | Gastrointestinal inflammatory disease | Chemokine GPCR | Lead mAb optimization | |
| P-015 | Lung fibrosis | Solid cancer | Wnt signal pathway | Lead mAb optimization | |
| P-016 | Diabetic retinopathy | Angiogenesis inhibitor | Peptide GPCR | Lead mAb optimization | |
| P-017 | Postoperative hypoglycemia | Pancreatic cancer | Peptide GPCR | Lead mAb optimization |
